OpenAdLibraryOpenAdLibrary
Affiliate & Media Buying

Native Ad Networks for Nutra Offers: What the Rules Say and Where to Test First

Native networks restrict deceptive health claims on paper, and how they treat nutra offers differs by network. A guide to comparing nutra rules; captured health ads are examples, not proof an ad was approved or compliant.

Editorial illustration: Native Ad Networks for Nutra Offers: What the Rules Say and Where to Test First

Native networks all publish rules that restrict health and supplement advertising, and no public data measures how strictly each one enforces them. The order this guide uses (Revcontent and MGID first, then Taboola and Outbrain, with the Microsoft-adjacent MSN feed and MediaGo last) is a planning assumption to test, not a measurement: the networks do not publish approval or enforcement rates, and we have no data showing that one is easier than another. This guide sets out what the networks' written rules say (checked 7 October 2026), what captured ads can and cannot tell you, and a testing sequence that treats the network order as a hypothesis. Captured ads are examples of what ran, not proof that their claims were approved, substantiated or lawful. OpenAdLibrary publishes this blog and sells a tool for researching captured ads.

What "nutra tolerance" can and cannot tell you#

Every network bans miracle cures on paper, and the written policies are the only fixed point, because enforcement is not published. In this guide, "tolerance" means how a network behaves across five practical axes, which we treat as questions to check rather than measured facts:

  • Claims aggressiveness. Does "Doctors are stunned" survive review, or does it bounce in an hour?
  • Advertorial pre-landers. Networks that allow story-style pre-landers still review them: Realize says it checks landing pages, and Revcontent and Outbrain require advertorial pages to carry a clear advertising label.
  • Imagery. Before/after photos are barred in thumbnails on Realize and Outbrain, Outbrain also bars zoomed-in body parts, and Revcontent bars before-and-after images in healthcare ads. Check each network's rules on other shock imagery.
  • Billing models. Subscription and trial offers carry extra disclosure rules: Realize requires auto-renewal terms to be disclosed clearly and conspicuously before purchase, with a specific opt-in, and US law adds its own requirements.
  • Enforcement style. Proactive review versus complaint-driven takedowns is a real difference in principle, but we found no published data on how each network enforces. Some publish review-time targets: Realize aims to review within one business day, and Revcontent's compliance team typically reviews manual submissions within 1 to 2 business days.

A network's willingness to run an ad is not legal clearance either. Every health claim on a nutra offer, express or implied, needs substantiation wherever it runs, and an ad that stays up on one network is not evidence that its claims are true or lawful. Operators who push claims further than they can support risk losing accounts and drawing regulator attention. The vertical's full offer and compliance landscape is covered in our nutra native ads guide.

A planning ladder, not a ranking#

Step (planning assumption) Networks What the published rules say about health and supplements (checked 7 October 2026) What we could not verify
1 Revcontent, MGID Revcontent: health claims that general knowledge cannot support need peer-reviewed substantiation; no claims of preventing, curing or reversing disease; no before-and-after images in healthcare ads; headlines must not make aggressive health claims or reference unrealistic timelines; supplement headlines and visuals may not compare the product with prescription medications; advertorial landing pages need an advertising notice. MGID: health products must avoid misleading claims, exaggerated results or unsafe practices, and supplements must comply with local regulations and avoid medical claims. How strictly either network enforces these rules, and approval rates for supplement offers
2 Taboola (Realize), Outbrain (Teads) Realize: no claim that a supplement diagnoses, cures, prevents, treats or reverses any disease; specific health claims need studies linked on the landing page; supplements need an FDA-style disclaimer and may not claim to be an alternative to, or more effective than, over-the-counter or prescription medicines; thumbnails must not show before/after photos. Outbrain: no illegitimate or unproven claims about results; no claim to diagnose, cure, prevent, treat or reverse any disease; no nootropics, "brain pills" or "smart drugs" meant to improve cognitive function; before-and-after photos are barred in thumbnails. Enforcement strictness and approval rates; Realize's page also lists an exception for supplements on well-known e-commerce sites
3 MediaGo, MSN feed Not reviewed for this update. Microsoft's and MediaGo's current health and supplement policies

We do not rank networks by captured ad counts. Counts of captured creatives describe what our collection captured and how our classifier labeled it, not demand, spend, approval rates or how strictly a network enforces its rules, and the per-network and category counts quoted in earlier versions of this guide have been withdrawn because we cannot reproduce them. A captured ad also does not show that its claims were approved or lawful.

Tier 1 (assumed easier to start on): Revcontent and MGID#

Revcontent's captured ads in June 2026 included "Surgeons: This Simple Trick Will End Knee Pain & Arthritis Quickly (Try It)" and "Endocrinologist: If You Have Diabetes, Read This Before It's Removed!", the latter in several variants at the same time. They are historical examples, their claims are not verified, and they may conflict with Revcontent's written rules, which say headlines must not make aggressive health claims, that claims of preventing, curing or reversing disease are not permitted, and that diabetes-related supplements may not be marketed as substitutes for medication. Several variants show an advertiser investing in an angle, not that the angle was approved or profitable. Revcontent says its compliance team typically reviews manual submissions within 1 to 2 business days, and its minimum daily campaign budget is $50. Platform mechanics are in how Revcontent works.

MGID says it covers 200+ countries and territories and 850M+ unique visitors a month (its own figures); whether its traffic suits advertorial funnels is something to test, not a given. Captured examples include "Doctors Call It 'Nature's Morphine' — Pain Relief Without A Prescription" and "Dentists Said Gums Can't Grow Back. Red Light Proves Them Wrong," each observed across 16 days (historical examples, claims not verified). A 16-day span does not show that the economics work, and a headline comparing a product to a prescription drug should be read against MGID's rules, which say health products must avoid misleading claims, exaggerated results or unsafe practices and supplements must avoid medical claims. MGID is prepaid CPC, with a $100 minimum deposit and at least $650 recommended. Setup details: how MGID native ads work.

Choosing between them is its own question — geo mix, minimums and audience differences are compared directly in MGID vs Revcontent. Some buyers run both, splitting by geo; treat any split as something to test in your own account.

Tier 2 (assumed more review): Taboola and Outbrain#

Why accept stricter review? Only if the audience justifies it, which is a question for your own test data: our captured counts cannot show volume or demand, and the health-creative counts quoted in earlier versions have been withdrawn. What the published rules allow is narrower. Realize bars any claim that a supplement diagnoses, cures, prevents, treats or reverses a disease, wants studies linked on the landing page for specific health claims, requires an FDA-style supplement disclaimer, bars supplements from claiming to be an alternative to, or more effective than, over-the-counter or prescription medicines, and reviews titles, thumbnails, destination URLs and landing pages. Outbrain's guidelines add that nootropics, "brain pills" and "smart drugs" are not allowed. The nutra captured on these networks includes supplement brands, health apps, telehealth intake funnels and device offers, but captures do not show how their claims were reviewed.

Rewriting an angle for a network with narrower rules is a skill, but treat it as compliance work, not as evasion. An angle that works on one network has to be rebuilt to the claims standard of the next: dropping disease names, cure verbs, outcome timelines and before/after imagery, and making sure every remaining claim, including implied ones, is true and substantiated. The angle (the curiosity gap, the mechanism story, the authority figure) can carry over, but the claims have to be rechecked each time, and "proved cheaply downstream" is not evidence that an angle is profitable or lawful.

A concrete rewrite shows the idea. The captured headline "Doctors Call It 'Nature's Morphine' — Pain Relief Without A Prescription" compares a product to a prescription drug, which the networks' written rules address: Realize bars supplements from claiming to be an alternative to, or more effective than, over-the-counter or prescription medicines, Revcontent says supplement headlines and visuals may not draw direct comparisons to prescription medications or imply equivalence, and MGID's rules on medical claims also point against it. A rewrite for narrower rules drops the drug comparison and the outcome promise: "Why Doctors Are Studying This Traditional Root for Everyday Aches." That version still implies that doctors are studying the root, which must be true and supportable, so treat it as a starting point for review, not as defensible on its face. If the softened version stops pulling clicks, the original's appeal may have been the claim itself, which is a reason to drop it rather than to scale it elsewhere.

Volume can slow review. Revcontent lists excessive content submission as a denial reason and notes that submitting a high volume of content in a short window of time may prevent its policy team from reviewing campaigns in a timely manner, so submit in small batches rather than flooding review with twenty variants. We have no data showing that warming an account with clean campaigns changes review outcomes on any network, so do not rely on it as a tactic; the safer approach is to submit only creative and pages you are confident meet the written rules.

Tier 3 (not reviewed): MediaGo and the MSN feed#

We have not reviewed Microsoft's or MediaGo's current health and supplement advertising policies for this update, so we make no claim about how open either feed is to nutra. Earlier versions of this guide said these feeds run strict, brand-safe review and clear little classic nutra; we cannot support that. MSN inventory can also be bought through Outbrain, which offers a "Run on MSN exclusively" feature, so the policy that applies depends on the platform you buy through. Before building for either feed, read the current policy for your product and market.

Billing models and disclosures#

Nutra offers differ as much in billing as in claims, and billing terms are a compliance issue too.

  • Straight sale (single purchase, clear price): has the fewest billing disclosures to get wrong. Approval still depends on the product, the claims and the landing page, and we have not reviewed what Tier-3 feeds require.
  • Subscription with disclosed terms: Realize requires the terms to be disclosed clearly and conspicuously before purchase, with a specific opt-in to auto-renewal, and in the US the Restore Online Shoppers' Confidence Act requires clear disclosure of material terms before billing information is taken, express informed consent before charging and a simple way to stop recurring charges. We do not know what drives each network's enforcement, so do not assume chargeback rates are the only concern.
  • Trial-and-rebill: the classic nutra structure, and the one with the most rules. Realize says a campaign may only reference a "trial" if it discloses the length of the trial, and may only call a product "free" if the claim is immediately followed by a disclosure of the subscription details. Check each network's current rules for free-trial and subscription offers before you build around rebill economics.
  • Listicle-to-store: an advertorial listicle ("5 supplements reviewed") feeding a standard ecommerce store. A network still reviews the product being sold and the claims in the ad and on the page, and Realize prohibits techniques that hide the true destination to bypass review, so do not assume a store page changes how the offer is treated.

The practical read: billing structure affects compliance and which networks you can use, not just lifetime value. An offer owner who builds a straight-sale SKU alongside a subscription offer has more options, as long as each offer is disclosed and supported on its own terms.

Geo strategy: what to check before going international#

Some buyers look beyond Tier-1 English geos in search of lower click costs and less competition, but we have no sourced CPC or competition data by geo. Whether an angle still works in translation is a test result, not a given. Three practical rules for going international:

  1. Translate the angle, not the words. Authority figures, mechanism stories and avoid-lists may carry across markets, but the authority archetype and the reference foods or objects need to be local. A literal translation of a US advertorial can read as foreign, which is worth testing before you scale.
  2. Check payout parity. A cheap click is not an edge if the offer pays a fraction of the US CPA. The geo-tier economics have to work end-to-end.
  3. Mind local regulation. Health-claim rules vary by country. The FTC guidance described below covers US advertising only, and other markets have their own rules, so get qualified local advice for each market. The network's geo-level policies are the first checkpoint, not the last.

Going geo-by-geo with an angle that has worked in your own tests is one way to scale, and moving to networks with narrower rules is another. Both depend on your own results, and we have no data on how often an angle tested in one geo carries over to another.

What captured ads can and cannot show about nutra#

Beyond the published rules, three patterns in the June 2026 captures are worth reading carefully, because each is easy to over-read.

The same advertiser can appear on more than one network. Health Weekly, for example, appears in our captures on both Outbrain and Revcontent, with more aggressive wording on Revcontent. That shows what was captured on each network. It does not show that the advertiser tuned its claims to each network's rules, or that the wording was approved under them.

Captured health ads are not a measure of demand. In our June 2026 captures health was one of the largest classified categories, but those counts describe what we captured and how we classified it, not demand, market size or whether health offers are profitable, and the counts quoted in earlier versions have been withdrawn. If many advertisers use similar angles, differentiation matters; study the most common native ad angles before writing your own.

Multi-variant runs show investment, not proof. When the same advertiser runs several near-identical variants of one creative at the same time, as the diabetes-angle advertiser above did on Revcontent, it may be testing or scaling an angle, but captures do not show spend, results or review outcomes, so you cannot tell which, or whether the claims were approved. Clusters like these are still useful research targets: the variant set shows which elements the advertiser chose to iterate on (image swaps versus headline swaps versus geo splits). Use them to form hypotheses to test, and check every claim against the network's written rules and applicable law before borrowing any of it.

A network's approval does not change the law. In the US, FTC staff's Health Products Compliance Guidance says claims about health benefits or safety need competent and reliable scientific evidence, which for health benefits will generally mean randomized, controlled human clinical testing, and that advertisers should not make claims through testimonials or expert endorsements that they could not substantiate if they made them directly. It also says all parties who participate directly in marketing and promotion have an obligation to make sure claims are presented truthfully, and that the FTC has acted against ad agencies and others, so whether a network or affiliate carries liability depends on the facts. The FTC's native advertising guide says a native ad must be readily identifiable as advertising, with disclosures needed on both the publisher's site and the click-through page unless that page is obviously an ad; the specifics are in our guide to FTC disclosure rules for advertorials and native ads. This is general information, not legal advice, and health claims need qualified review for each market.

The practical translation for nutra: every claim, including implied ones, needs evidence before it runs, on any network. Build offers you can keep running within the written rules.

A cautious testing sequence#

  1. Research before spend. Pull the captured nutra ads on Revcontent and MGID: filter by health category and your geo (filters need the Founders plan; the free plan shows the 20 newest ads) and sort by days running. Creatives observed for several weeks are a shortlist of angles to study, not evidence of what works. Check each one's claims against the network's written rules.
  2. Test on Tier 1. Launch angle variants on Revcontent or MGID, within their written rules. We found no published typical CPC for either network, so size the test from your own economics: Revcontent's minimum daily campaign budget is $50, and MGID's minimum deposit is $100 (at least $650 recommended). For example, a hypothetical $40 target CPA and a 2% landing-page conversion rate give a break-even CPC of $0.80; use your own numbers.
  3. Judge on funnel metrics, not CTR alone. Curiosity headlines can earn clicks that never convert, so look at pre-lander read-through, cart starts and conversions.
  4. Move up carefully. Rebuild angles that worked in your own tests to the next network's written claim standards, check the landing page against that network's rules, and scale only if the economics hold.
  5. Wire conversion data back before scaling. Use a tracker with postbacks that feed conversions back to the platform where it supports them, and use publisher or widget-level reporting to build a list of placements that produce for you during the test phase.
  6. Watch for fatigue and copycats. Angles that seem to work may be copied; we have no data on how quickly. Watching captured ads for lookalikes of your angle can prompt a creative review, but only your own results can show fatigue.

Picking your first network#

If you start with one network, choose by your offer's geo and the network's current rules for your product, not by a ranking: this guide has no data showing that one network is better for nutra. If you run two, let your own geo split and results decide. Move to a network with narrower rules only with angles and pages that already meet its written policy and have paid for themselves in your own tests. The ladder is a sequencing idea, not a quality ranking. And whichever network you start on, start with the research pass, not the launch button: captured ads show what competitors chose to run, which is cheaper to learn than your own test budget, though they do not show what worked.

Frequently asked questions

Which native ad network is easiest for nutra offers?
No public data answers this. All four major native networks publish rules that restrict health and supplement claims, and approval depends on your product, claims and landing page. Published minimums (Revcontent's is $50 a day per campaign, and MGID's is a $100 deposit) say nothing about how readily either network accepts supplement offers. Read each network's current policy for your product before you build.
Can nutra offers run on Taboola or Outbrain?
Yes, within their written rules. Realize (Taboola) bars claims that a supplement diagnoses, cures, prevents, treats or reverses any disease, requires an FDA-style disclaimer, wants studies linked on the landing page for specific health claims, and does not allow before/after photos in thumbnails. Outbrain bars unproven claims about results, disease claims, nootropics and before-and-after thumbnails. Realize reviews landing pages as well as ads, and Outbrain's guidelines include landing-page requirements. Approval of an ad is not legal clearance, and captured ads on either network do not show that their claims were allowed.
Which geos should I test for nutra on native ads?
No public data says which geos work best. Tier-1 English geos may be more competitive and Tier-2 and Tier-3 markets may offer cheaper clicks, but we have no sourced CPC or payout data by geo, so test with your own numbers. The rule is end-to-end parity: a cheap click only helps if the offer's local payout supports it. Health-claim regulation varies by country, so check each network's geo policies and get qualified local advice first.
Are advertorial pre-landers allowed for nutra offers?
Often, with conditions that differ by network. Revcontent requires a clear "Advertisement", "Sponsored" or "Paid Content" notice at the top of advertorial landing pages, and Outbrain requires "Advertisement" or "Advertorial" to appear prominently at the top of applicable pages. FTC guidance says a native ad must be readily identifiable as advertising, with disclosures needed on both the publisher's site and the click-through page unless that page is obviously an ad. Review the pre-lander as rigorously as the ad itself, because networks review landing pages and the claims on them.
How much budget does it take to test a nutra offer on native?
It depends on your payout and conversion rate, and no public source gives a standard test budget. Network minimums are a floor, not a test budget: Revcontent's minimum daily campaign budget is $50, MGID's minimum deposit is $100 (at least $650 recommended), Outbrain requires at least $20 a day and $600 a month, and Realize recommends a daily budget of 10 times your CPA goal or at least $50. A common rule of thumb, not a measured standard, is to fund each angle-network combination with several multiples of one conversion's payout before judging results. Judge on pre-lander read-through, cart starts and conversions rather than CTR alone, and wire conversion postbacks before scaling.
The OpenAdLibrary Team
Written byThe OpenAdLibrary Team
Ad intelligence & native advertising research

We build OpenAdLibrary, the open ad-transparency platform. Every day our systems capture live native ads across Taboola, Outbrain, MGID, Revcontent, Teads, Yahoo and MSN, identify the real advertiser behind each one, and follow the click to its landing page. These guides distill what we see in that data so you can research the market faster.